Chengda Pharmaceuticals Co (SZSE:301201) Ending Cash Position: ¥229.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301201 Chengda Pharmaceuticals Co Ltd SZSE:301201
75 GF Score
Price ¥34.59
GF Value ¥33.37
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Chengda Pharmaceuticals Co Ending Cash Position?

Chengda Pharmaceuticals Co SZSE:301201 -4.82% 75 Ending Cash Position is ¥229.8 Mil as of Jun. 2026. GuruFocus rates SZSE:301201 with a GF Score™ of 75/100 and a GF Value™ of ¥33.37 (Fairly Valued). The stock has 4 warning signs investors should review.

Chengda Pharmaceuticals Co's Ending Cash Position for the quarter that ended in Jun. 2026 was ¥229.8 Mil.

Chengda Pharmaceuticals Co's quarterly Ending Cash Position increased from Dec. 2025 (¥424.3 Mil) to Mar. 2026 (¥429.6 Mil) but then declined from Mar. 2026 (¥429.6 Mil) to Jun. 2026 (¥229.8 Mil).

Chengda Pharmaceuticals Co's annual Ending Cash Position declined from Dec. 2023 (¥1,362.7 Mil) to Dec. 2024 (¥176.9 Mil) but then increased from Dec. 2024 (¥176.9 Mil) to Dec. 2025 (¥424.3 Mil).

Chengda Pharmaceuticals Co Ending Cash Position Related Terms

Chengda Pharmaceuticals Co Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Chengda Pharmaceuticals Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengda Pharmaceuticals Co Ending Cash Position Chart

Chengda Pharmaceuticals Co Annual Data
Trend Dec10 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.49 604.43 1,362.69 176.94 424.27

Chengda Pharmaceuticals Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 818.58 804.22 424.27 429.56 229.80
SZSE:301201
75GF Score
Chengda Pharmaceuticals Co Ltd SZSE:301201
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chengda Pharmaceuticals Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Chengda Pharmaceuticals Co's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=176.942+247.323
=424.3

Chengda Pharmaceuticals Co's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=429.561+-199.757
=229.8

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ¥229.8 Mil mean?
Chengda Pharmaceuticals Co (SZSE:301201) has a Ending Cash Position of ¥229.8 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Chengda Pharmaceuticals Co and its competitors.
Is Chengda Pharmaceuticals Co's Ending Cash Position too high?
Chengda Pharmaceuticals Co's current Ending Cash Position is ¥229.8 Mil. Overall, Chengda Pharmaceuticals Co has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chengda Pharmaceuticals Co's Ending Cash Position compare to ZTS?
Chengda Pharmaceuticals Co's Ending Cash Position of ¥229.8 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Chengda Pharmaceuticals Co and its competitors. Chengda Pharmaceuticals Co's current Ending Cash Position is ¥229.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengda Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengda Pharmaceuticals Co (SZSE:301201) is currently considered Fairly Valued. The stock's GF Value™ is ¥33.37, compared to a current price of ¥34.59 — trading 3.7% above its estimated fair value. The current Ending Cash Position is ¥229.8 Mil. Chengda Pharmaceuticals Co's overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Chengda Pharmaceuticals Co (SZSE:301201), the current Ending Cash Position is ¥229.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chengda Pharmaceuticals Co (SZSE:301201) Overvalued in 2026?

Based on GuruFocus' analysis, Chengda Pharmaceuticals Co stock appears to be overvalued. The current stock price of ¥34.59 is trading 3.7% above its estimated GF Value™ of ¥33.37. GuruFocus considers Chengda Pharmaceuticals Co to be Fairly Valued.

Key valuation signals for SZSE:301201:

  • Ending Cash Position: ¥229.8 Mil
  • GF Value™: ¥33.37 vs. price of ¥34.59 (3.7% above fair value)
  • GF Score™: 75/100 with 4 warning signs

No single metric tells the full story. See the SZSE:301201 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengda Pharmaceuticals Co Business Description

Address 36 Huanghe Road, Huimin Street, Jiashan County, Zhejiang Province, Jiaxing, CHN, 314100
Chengda Pharmaceuticals Co Ltd is engaged in the research and development, production and sales of L-carnitine series products. The company mainly produces raw materials, food additives, feed additives, antibiotics, anti-cancer, anti-virus and other series of pharmaceutical intermediates. The products are sold to more than 30 countries and regions.
75GF Score

Get the complete analysis for SZSE:301201

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥34.59
Price
¥33.37
GF Value